Data-driven taxonomy for antipsychotic medication: a new classification system
<p><strong>Background</strong></p> Globally, there are more than 25 licensed antipsychotic medications. Antipsychotics are commonly described as either typical or atypical, but this dichotomous classification does not reflect the diversity of their pharmacological and clinica...
| Asıl Yazarlar: | , , , , , |
|---|---|
| Materyal Türü: | Journal article |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
Elsevier
2023
|
| _version_ | 1826311119212380160 |
|---|---|
| author | McCutcheon, RA Harrison, PJ Howes, OD McGuire, PK Taylor, DM Pillinger, T |
| author_facet | McCutcheon, RA Harrison, PJ Howes, OD McGuire, PK Taylor, DM Pillinger, T |
| author_sort | McCutcheon, RA |
| collection | OXFORD |
| description | <p><strong>Background</strong></p>
Globally, there are more than 25 licensed antipsychotic medications. Antipsychotics are commonly described as either typical or atypical, but this dichotomous classification does not reflect the diversity of their pharmacological and clinical profiles. There is a need for a data-driven antipsychotic classification scheme suitable for clinicians and researchers that maps onto both pharmacological and clinical effects. Receptor affinity provides one starting point for such a scheme.
<p><strong>Methods</strong></p>
We analyzed affinities of 27 antipsychotics for 42 receptors from 3325 in vitro receptor binding studies. We used a clustering algorithm to group antipsychotics based on receptor affinity. Using a machine learning model, we examined the ability of this grouping to predict antipsychotic-induced clinical effects quantified according to an umbrella review of clinical trial and treatment guideline data.
<p><strong>Results</strong></p>
Clustering resulted in 4 groups of antipsychotics. The predominant receptor affinity and clinical effect “fingerprints” of these 4 groups were defined as follows: group 1, muscarinic (M2–M5) receptor antagonism (cholinergic and metabolic side effects); group 2, dopamine (D2) partial agonism and adrenergic antagonism (overall low side-effect burden); group 3, serotonergic and dopaminergic antagonism (overall moderate side-effect burden); and group 4, dopaminergic antagonism (extrapyramidal side effects and hyperprolactinemia). Groups 1 and 4 were more efficacious than groups 2 and 3. The classification was shown to predict out-of-sample clinical effects of individual drugs.
<p><strong>Conclusions</strong></p>
A receptor affinity–based grouping not only reflects compound pharmacology but also detects meaningful clinical differences. This approach has the potential to benefit both patients and researchers by guiding treatment and informing drug development. |
| first_indexed | 2024-03-07T08:03:40Z |
| format | Journal article |
| id | oxford-uuid:7978fafe-26c6-47e9-959d-0c6f90bef87a |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:03:40Z |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:7978fafe-26c6-47e9-959d-0c6f90bef87a2023-10-16T08:42:30ZData-driven taxonomy for antipsychotic medication: a new classification systemJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7978fafe-26c6-47e9-959d-0c6f90bef87aEnglishSymplectic ElementsElsevier2023McCutcheon, RAHarrison, PJHowes, ODMcGuire, PKTaylor, DMPillinger, T<p><strong>Background</strong></p> Globally, there are more than 25 licensed antipsychotic medications. Antipsychotics are commonly described as either typical or atypical, but this dichotomous classification does not reflect the diversity of their pharmacological and clinical profiles. There is a need for a data-driven antipsychotic classification scheme suitable for clinicians and researchers that maps onto both pharmacological and clinical effects. Receptor affinity provides one starting point for such a scheme. <p><strong>Methods</strong></p> We analyzed affinities of 27 antipsychotics for 42 receptors from 3325 in vitro receptor binding studies. We used a clustering algorithm to group antipsychotics based on receptor affinity. Using a machine learning model, we examined the ability of this grouping to predict antipsychotic-induced clinical effects quantified according to an umbrella review of clinical trial and treatment guideline data. <p><strong>Results</strong></p> Clustering resulted in 4 groups of antipsychotics. The predominant receptor affinity and clinical effect “fingerprints” of these 4 groups were defined as follows: group 1, muscarinic (M2–M5) receptor antagonism (cholinergic and metabolic side effects); group 2, dopamine (D2) partial agonism and adrenergic antagonism (overall low side-effect burden); group 3, serotonergic and dopaminergic antagonism (overall moderate side-effect burden); and group 4, dopaminergic antagonism (extrapyramidal side effects and hyperprolactinemia). Groups 1 and 4 were more efficacious than groups 2 and 3. The classification was shown to predict out-of-sample clinical effects of individual drugs. <p><strong>Conclusions</strong></p> A receptor affinity–based grouping not only reflects compound pharmacology but also detects meaningful clinical differences. This approach has the potential to benefit both patients and researchers by guiding treatment and informing drug development. |
| spellingShingle | McCutcheon, RA Harrison, PJ Howes, OD McGuire, PK Taylor, DM Pillinger, T Data-driven taxonomy for antipsychotic medication: a new classification system |
| title | Data-driven taxonomy for antipsychotic medication: a new classification system |
| title_full | Data-driven taxonomy for antipsychotic medication: a new classification system |
| title_fullStr | Data-driven taxonomy for antipsychotic medication: a new classification system |
| title_full_unstemmed | Data-driven taxonomy for antipsychotic medication: a new classification system |
| title_short | Data-driven taxonomy for antipsychotic medication: a new classification system |
| title_sort | data driven taxonomy for antipsychotic medication a new classification system |
| work_keys_str_mv | AT mccutcheonra datadriventaxonomyforantipsychoticmedicationanewclassificationsystem AT harrisonpj datadriventaxonomyforantipsychoticmedicationanewclassificationsystem AT howesod datadriventaxonomyforantipsychoticmedicationanewclassificationsystem AT mcguirepk datadriventaxonomyforantipsychoticmedicationanewclassificationsystem AT taylordm datadriventaxonomyforantipsychoticmedicationanewclassificationsystem AT pillingert datadriventaxonomyforantipsychoticmedicationanewclassificationsystem |